Summit Therapeutics PLC is an innovative biopharmaceutical company headquartered in Cambridge, Massachusetts, specializing in the development of novel therapies for infectious diseases. Leveraging its proprietary drug development platforms, Summit addresses significant unmet medical needs in the U.S., Latin America, and Europe. With a strategic emphasis on advancing therapeutic options that enhance patient care, the company is positioned as a pivotal player in the biopharmaceutical sector, aiming to improve the quality of life for individuals facing severe infections through its groundbreaking research and development initiatives. Show more

Location: 601 BRICKELL KEY DRIVE, MIAMI, FL, UNITED STATES, 33131, Miami, FL, 33131, USA | Website: https://www.smmttx.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE

Market Cap

10.31B

52 Wk Range

$13.83 - $36.91

Previous Close

$13.85

Open

$14.12

Volume

2,708,912

Day Range

$14.04 - $15.11

Enterprise Value

10.5B

Cash

238.6M

Avg Qtr Burn

-93.08M

Insider Ownership

86.05%

Institutional Own.

14.16%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Ivonescimab + chemotherapy Details EGFR-mutated, advanced non-squamous NSCLC (2L+ EGFRm NSCLC)	PDUFA Approval decision	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Ivonescimab Details 1L PD-L1 positive Non-small cell lung carcinoma	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Ivonescimab + Chemotherapy Details Squamous NSCLC	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Ivonescimab (SMT112) Details 1L Non-small cell lung carcinoma	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Ivonescimab + chemotherapy Details EGFR-mutated, advanced non-squamous NSCLC	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Ivonescimab Details PD-L1 positive NSCLC	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Ivonescimab (SMT112) +Chemotherapy Details Biliary Tract Cancer	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Ivonescimab Details Colorectal cancer (CRC)	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Ridinilazole Details Intestinal infection, Bacterial infection	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.